拜玛林制药 BMRN 深 沪
已收盘 12-19 16:00:00 美东时间
61.13
+9.180
+17.67%
华盛通- 最 高63.89
- 今 开54.74
- 成交量 1425.54万股
- 最 低 50.90
- 昨 收 51.95
- 总市值 113.09亿
- 52周最高 73.51
- 市盈率 静 --
- 换手率 7.71%
- 52周最低 50.76
- 委 比 -9.71%
- 总股本 1.85亿
- 历史最高 151.75
- 量 比 7.94
- 振 幅 25.00%
- 历史最低 1.10
- 每 手 1
- 风险率 5.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
今天 01:16
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
今天 00:07
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
12-19 23:36
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
Inozyme Pharma has postponed its 2025 Annual Meeting due to the pending acquisition by BioMarin Pharmaceutical Inc. If the acquisition is completed, the Annual Meeting will not occur. If not, the Board will decide on further steps to reschedule the meeting.
06-20 21:00
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
Biomerica's inFoods® IBS product reduces GI pain and bloating by 48.5% and 49.8% respectively, utilizing personalized dietary adjustments and a real-time feedback system to enhance symptom management.
05-22 12:19
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past...
2024-09-23 22:00
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-17 21:00
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
2024-09-06 23:52
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth.
2024-09-05 21:51
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 14 analysts ...
2024-09-05 21:00
